News | June 25, 2007

Ultrasound Proves Safe Alternative to Biopsy in Some Breast Masses

June 26, 2007 - Researchers have reported that breast masses shown on ultrasound that are diagnosed as "probably benign" can be safely managed with imaging follow-up rather than biopsy, according to a study appearing in the July issue of Radiology.

"These findings indicate that ultrasound follow-up can spare women from unnecessary, invasive biopsies," said Oswald Graf, M.D., from the Department of Radiology, Ambulatory Care Center in Steyr, Austria.

According to recently introduced Breast Imaging Reporting and Data System (BI-RADS) guidelines for ultrasound, a solid mass with circumscribed (confined) margins, oval shape and parallel orientation can be classified as probably benign (category 3). Dr. Graf's study is the first to report outcomes from ultrasound follow-up of masses that were classified as probably benign at initial ultrasound.

"Our study shows that following a lesion classified in the BI-RADS lexicon as category 3 is a safe alternative to immediate biopsy," Dr. Graf said. "But it is essential that lesions strictly meet these criteria."

The researchers retrospectively studied 409 women with 448 nonpalpable masses that were partially or completely obscured at mammography by dense breast tissue and were classified as probably benign at ultrasound. After initial imaging with mammography and ultrasound, follow-up was performed in 445 masses. The other three masses were biopsied and shown to be benign.

At follow-up every six months over two to five years, 442 of the 445 masses remained stable. Two masses increased but were found benign at biopsy, and one mass became palpable, and cancer was diagnosed at biopsy. The findings indicate an overall negative predictive value of 99.8 percent. In other words, only one in 445 masses (0.2 percent) developed into cancer. The results indicate that routine follow-up with ultrasound is a safe alternative to biopsy in cases where the breast lesion is classified as probably benign.

"More studies are needed to define the role of ultrasound in breast cancer screening," Dr. Graf said. "However, these findings suggest that the negative effects of incidental findings may be limited principally to patient anxiety and the cost of follow-up imaging, as opposed to conducting a large number of benign biopsies."

For more information: www.RSNA.org/radiologyjnl

Related Content

Siemens Healthineers Launches Acuson Sequoia Ultrasound
Technology | Ultrasound Imaging | July 12, 2018
July 12, 2018 — Siemens Healthineers recently announced the launch of its new ultrasound system, the Acuson Sequoia.
EchoNous Vein Receives FDA Approval to Improve First-Time Peripheral IV Catheter Insertion
Technology | Ultrasound Imaging | July 12, 2018
EchoNous has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the EchoNous Vein, an ultrasound-...
Hologic Announces Availability of Viera Portable Breast Ultrasound System
Technology | Ultrasound Women's Health | July 11, 2018
Hologic’s new Viera portable breast ultrasound system is now available for purchase in the United States and Europe....
Healcerion Receives FDA Approval for Sonon 300L Handheld Ultrasound Device
Technology | Ultrasound Imaging | July 09, 2018
South Korea-based Healcerion launched the Sonon 300L wireless handheld ultrasound device to the U.S. market following U...
Neural Analytics Inc. Receives CE Mark for Robotic Ultrasound System
Technology | Ultrasound Imaging | July 03, 2018
Medical robotics company Neural Analytics Inc. announced that it received CE Mark for its NeuralBot System, a robotic...
Konica Minolta Launches Sonimage MX1 Portable Ultrasound System
Technology | Ultrasound Imaging | June 28, 2018
Konica Minolta Healthcare Americas Inc. introduced the Sonimage MX1 portable ultrasound system, optimized for...
EchoMD AutoEF Software Improves Variability in Ejection Fraction Estimation
News | Cardiovascular Ultrasound | June 27, 2018
A recent study conducted with the Minneapolis Heart Institute found that Bay Labs’ EchoMD AutoEF deep learning software...
Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
Epsilon Imaging Demonstrates Strain Imaging Integration for Echo Programs at ASE 2018
News | Cardiovascular Ultrasound | June 19, 2018
Clinical practice, along with guidelines and research, have shown that speckle tracking strain imaging can improve...
FDA Clears Bay Labs' EchoMD AutoEF Software for AI Echo Analysis
Technology | Cardiovascular Ultrasound | June 19, 2018
Cardiovascular imaging artificial intelligence (AI) company Bay Labs announced its EchoMD AutoEF software received 510(...
Overlay Init